<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143579">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231659</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001JIL05</org_study_id>
    <nct_id>NCT01231659</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a multi-center, Israeli phase II open label study evaluating treatment with RAD001
      (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after
      recurrence or progression on Tamoxifen, Anastrozole or Examestane.

      There are no treatments specifically approved after recurrence or progression on AIs.
      Available options, based on common clinical practice and several treatment guidelines (e.g.
      NCCN treatment guidelines 2008), include fulvestrant.

      Combining RAD001 with letrazole is a rational approach to the treatment of advanced Brest
      Cancer, offering the potential for inhibition of tumor cell growth\ proliferation and anti
      angiogenesis while at the same time potentially preventing the development of letrazole
      resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>until 1st progression</time_frame>
    <description>imaging every 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>until 1st progression</time_frame>
    <description>imaging every 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years after LPLV</time_frame>
    <description>by phone call to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>until disease progression</time_frame>
    <description>imaging every 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile</measure>
    <time_frame>All study duration</time_frame>
    <description>Adverse Events Serious Adverse Events, abs, ECG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Postmenopausal Women</condition>
  <condition>Locally Advanced Metastatic Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 10 mg + Letrozole 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus + Letrozole</intervention_name>
    <arm_group_label>Everolimus + Letrozole</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with estrogen receptor positive locally advanced or metastatic
             breast cancer after documented recurrence or progression on Tamoxifen, Anastrozole or
             Examestane.

               -  Refractory disease to hormonal therapy is defined as:

                    1. Recurrence while on, or within 12 month of end of, adjuvant treatment with
                       Tamoxifen , Anastrozole, or Exemestane.

                    2. Recurrence while on, or within 24 month of end of, adjuvant treatment with
                       Letrozole.

                    3. Progression while on Tamoxifen, Anastrozole or Exemestane treatment for
                       locally advanced or metastatic breast cancer.

        Exclusion Criteria:

          -  Prior use of chemotherapy and letrozole for Advanced Breast Cancer and mTOR
             inhibitors as the last anticancer treatment prior to study entry.

          -  Patients must have radiological evidence of recurrence or progression on last therapy
             prior to study entry.

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 26, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAD001 (Everolimus)</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Metastatic Breast cancer</keyword>
  <keyword>Estrogen receptor positive</keyword>
  <keyword>Failure of Tamoxifen</keyword>
  <keyword>Anastrozole or Examestane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
